Showing results (91-100 of 115) with videos related to

Sort By:
Pageof 12
The British Journal of Dermatology|July 6, 2022
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)Andrew Blauvelt, Alexa B Kimball, Matthias Augustin, et al.
The Journal of Dermatology|February 1, 2021
Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1)Shinichi Imafuku, Hidemi Nakagawa, Atsuyuki Igarashi, et al.
The Journal of Dermatology|February 26, 2025
Risankizumab in Japanese patients with moderate-to-severe palmoplantar pustulosis: Results from the randomized, phase 3 JumPPP studyYukari Okubo, Masamoto Murakami, Satomi Kobayashi, et al.
The Journal of Dermatology|October 25, 2022
Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled Effisayil™ 1 studyAkimichi Morita, Tsen-Fang Tsai, Evelyn Yap Wen Yee, et al.
Modern Rheumatology|December 30, 2021
SAPHO syndrome and pustulotic arthro-osteitisMitsumasa Kishimoto, Yoshinori Taniguchi, Shigeyoshi Tsuji, et al.
Dermatology and Therapy|January 17, 2023
Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled StudyAkihiko Asahina, Yukari Okubo, Akimichi Morita, et al.
The British Journal of Dermatology|November 11, 2023
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.
JAMA Dermatology|May 11, 2022
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical TrialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.
The Journal of Dermatology|August 6, 2026
Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension TrialsYukari Okubo, Akimichi Morita, Yayoi Tada, et al.
The Journal of Dermatology|July 9, 2019
Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativaAkimichi Morita, Hidetoshi Takahashi, Kentaro Ozawa, et al.
Pageof 12